The FDA decision regarding Vanda Pharmaceuticals Inc.’s (VNDA) investigational motion-sickness drug, Tradipitant, is anticipated on December 30, 2025.The company licensed Tradipitant from Eli Lilly in April 2012. Tradipitant is a neurokinin-1 receptor antagonist. It is designed to block the NK-1 receptor, which is found in many tissues but is most active in the nervous system. Normally, the chemical Substance P binds to this receptor and helps regulate inflammation, pain signals, stress responses, cravings, and nausea/vomiting.When Substance P activates the NK-1 receptor too much, either in the brain or elsewhere, it can contribute to conditions such as anxiety, addiction, nausea/vomiting, and itching. By blocking this receptor, Tradipitant may help reduce this over-stimulation and improve symptoms related to these conditions.Motion sickness is one of the most prevalent episodic disorders in the world, whose prevalence has significantly increased with world population mobility over the last 100 years. The FDA has not approved a new medication for motion sickness since 1979, when Scopolamine - a transdermal patch applied behind the ear - received approval. VNDA closed Wednesday’s (November 26, 2025) trading at $5.30, up 6%.